Karyopharm Therapeutics Inc

KPTI

NASDAQ. Currency in USD

4.70 +0.11 ( +2.40% )

Real time prices: December 09

Market Cap.
381.43M
Beta (5Y monthly)
-0.12
Price/Earnings
-
EPS (TTM)
-1.14
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
1.73M
1y Target Est.
9.67
Day's Range
4.50
-
4.72
52 Week's Range
4.00
-
14.73

Historical Summary

Performance
EPS growth
Share Buybacks

About Karyopharm Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.karyopharm.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
75.55M
Employees
442
Address
85 Wells Avenue, Newton, MA, United States, 02459
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Latest news

Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 96% as Wall Street Analysts Expect?
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 96% as Wall Street Analysts Expect?

The mean of analysts' price targets for Karyopharm Therapeutics (KPTI) points to a 96.1% upside...
By Zacks Investment Research - 4 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022

Upgrades Citigroup upgraded the previous rating for Advanced Energy Industries Inc (NASDAQ:AEIS) from Neutral to...
By Benzinga - 5 weeks ago

Under Armour To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday
Under Armour To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday

Telsey Advisory Group raised Under Armour, Inc.. (NASDAQ: UAA) price target from $8 to $9....
By Benzinga - 5 weeks ago

Karyopharm Therapeutics (KPTI) Q3 2022 Earnings Call Transcript
Karyopharm Therapeutics (KPTI) Q3 2022 Earnings Call Transcript

KPTI earnings call for the period ending September 30, 2022.
By The Motley Fool - 5 weeks ago

Aziyo Biologics, Inc. (AZYO) Soars 11.7%: Is Further Upside Left in the Stock?
Aziyo Biologics, Inc. (AZYO) Soars 11.7%: Is Further Upside Left in the Stock?

Aziyo Biologics, Inc. (AZYO) saw its shares surge in the last session with trading volume...
By Zacks Investment Research - 6 weeks ago

Ryder System, Harrow Health And Other Big Gainers From Tuesday
Ryder System, Harrow Health And Other Big Gainers From Tuesday

U.S. stocks closed mixed with the Dow Jones dropping around 125 points on Tuesday. Here...
By Benzinga - 10 weeks ago

Expert Ratings for Karyopharm Therapeutics
Expert Ratings for Karyopharm Therapeutics

Analysts have provided the following ratings for Karyopharm Therapeutics (NASDAQ:KPTI) within the last quarter: Bullish...
By Benzinga - 13 weeks ago

Where Karyopharm Therapeutics Stands With Analysts
Where Karyopharm Therapeutics Stands With Analysts

Karyopharm Therapeutics (NASDAQ:KPTI) has observed the following analyst ratings within the last quarter: Bullish Somewhat...
By Benzinga - 13 weeks ago